Navigation Links
What Motivates Physicians to Succeed? Money Isn't Most Important
Date:5/13/2009

While doctors place considerable importance on their current and future earnings, compensation alone is not the greatest motivation for career satisfaction, according to an article entitled "Motivating Physicians" appearing in the latest issue of the Jackson & Coker Industry Report.

Alpharetta, GA (Vocus) May 12, 2009 -- While doctors place considerable importance on their current and future earnings, compensation alone is not the greatest motivation for career satisfaction, according to an article entitled "Motivating Physicians" appearing in the latest issue of the Jackson & Coker Industry Report. (http://www.jacksoncoker.com/physician-career-resources/newsletters/2009-april.aspx)



According to the article, written by an independent firm specializing in health care research, other important considerations factor into how motivated medical doctors are in practicing medicine in a manner that is personally and professionally rewarding. Key considerations that impact individual motivation include:

 
  • the amount of administrative duties
  • bureaucratic red tape
  • patient load
  • amount of individual autonomy
  • government overregulation
  • overall organizational morale.

The article points out the four internal factors that drive individuals to succeed and form the basis of individual motivation. It also discusses the "higher order needs&
'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Rejuvenating Fitness Program Motivates Participants to Spring Into Motion
2. Independence Blue Cross Motivates 60 Area Employers to Host National Walk @ Lunch Day Events on April 29
3. Money motivates doctors to reduce ethnic differences in heart disease treatments
4. Money motivates -- especially when your colleague gets less
5. YMCAs Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During America On the Move Week with the YMCA
6. Back-to-School Campaign Motivates Children and Parents to Embrace Habits for Health
7. Physicians for Human Rights and 20 Countries Demand Iran Release AIDS Doctors
8. Attention New Jersey Physicians Still Needing to Meet Cultural Competency Requirement by June 30
9. Physicians Choice Leverages InstaMeds Integrated Platform for Healthcare Payment & Clearinghouse Solutions
10. Dictation, Transcription Workflow and Document Management Platform Aids Physicians In Searching For Swine Flu Symptoms
11. Physicians Conduct Research Studies in Minutes, Not Months, at Montefiore Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
What Motivates Physicians to Succeed?  Money Isn't Most Important 
What Motivates Physicians to Succeed? Money Isn't Most Important
Other Medicine News:Health News:Secretary Shinseki Announces $215 Million in Projects for Rural Veterans 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 1Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 2VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 1VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 2